Emergent BioSolutions acquires Europe's Microscience

GAITHERSBURG, Md. — On June, 27, 2005, Emergent BioSolutions announced that it acquired England-based Microscience Ltd., a privately held vaccine company primarily involved in the research and development of proprietary vaccines and immunotherapeutics.

Emergent BioSolutions acquired Microscience through a share exchange agreement. The terms of the acquisition were not disclosed.

The acquisition will expand Emergent BioSolutions’ global operations into the European market. Emergent BioSolutions will also benefit from Microscience’s intellectual property portfolio composed of 18 patent families covering more than 350 genes, with 101 initial applications.

 “This is an exciting, transformational event for both Emergent and Microscience,” said Fuad El-Hibri, Emergent BioSolutions’ chairman and CEO. “With five vaccines in clinical development, valuable vaccine technology and delivery platforms, and a highly talented scientific and development team, Microscience fits squarely into Emergent’s strategic plan and significantly broadens our reach in the growing global vaccine market.”

As part of the transaction, Emergent BioSolutions is acquiring a broad product portfolio of five clinical-stage vaccines that target infectious diseases.

These include oral vaccines to protect against Typhoid (Phase II), traveler’s diarrhea caused by enterotoxigenic E. coli (completed Phase I) and a therapeutic vaccine to treat chronic carriers of Hepatitis B (completed Phase I). Early stage clinical trials for an injectable Meningitis B vaccine and a neonatal Group B Streptococcus vaccine are ongoing. A further oral vaccine program for anthrax is completing pre-clinical development.

Added El-Hibri, “Beyond its promising vaccine technology and portfolio of products, Microscience brings significant collaborations with respected international research organizations and a number of important commercial relationships and out-licensing agreements and opportunities with large pharmaceutical companies.”

Microscience is being re-named Emergent Europe and Dr. Steven Chatfield, Emergent BioSolutions’ senior vice president of research and development, has been appointed its CEO.

Emergent BioSolutions is focusing its efforts on developing biodefense vaccines and therapeutics, as well as products in the area of infectious diseases. The company’s portfolio of commercial products include: TracVax, a vaccine designed to prevent infections by Chlamydia trachomatis; and HeliVax, a vaccine designed to prevent infections by Helicobacter pylori, a leading bacterial cause of ulcers, gastric cancers and cardiac disease.